GSK stock heads into the open after a 1.0 percent drop

At the close on September 10, 2026, GSK stock finished at USD 48.12 on the NYSE, down 1.0 percent. The share price lagged the S&P 500, which ended at 7,591.70 points, as Japan approved a prefilled syringe version of Shingrix.

GSK stock closed at USD 48.12 on the NYSE on September 10, 2026, down 1.0 percent from the previous close. The move left the shares below the prior close of USD 48.63 and underperformed the S&P 500, which finished the session at 7,591.70 points.

September 10, 2026 in numbers

GSK plc (ISIN GB0009252882) traded between USD 48.11 and USD 48.66 during the session, with volume of 5,452,000 shares. The close sat 4.6 percent below the 52-week high of USD 50.44 and 12.7 percent above the 52-week low of USD 42.70.

As Reuters reported on September 10, 2026, Japan's Ministry of Health, Labour and Welfare approved a prefilled syringe presentation of Shingrix. That regulatory update gave the stock a fresh company-specific catalyst for the last session.

Today before the bell

Today, investors are also watching the August consumer price data in the US, a release that can shape rate expectations and broader healthcare sentiment. GSK also trades after the Japan approval news from the previous session.